 |
42 Diseases |  |
114 Trials |
|
114 Trials |  |
1654 News |  |
| «12...19202122232425262728293031» |
- || guadecitabine (SGI-110) / Otsuka
Trial primary completion date, Combination therapy: SGI-110 in Combination With Carboplatin in Ovarian Cancer (clinicaltrials.gov) - Dec 29, 2015
P1/2, N=116, Active, not recruiting, Sponsor: Astex Pharmaceuticals
Trial primary completion date: Jun 2015 --> Mar 2016
- || bortezomib / Generic mfg., pegylated liposomal doxorubicin / Generic mfg., bendamustine / Generic mfg.
Trial primary completion date, Combination therapy: Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma (clinicaltrials.gov) - Dec 29, 2015
P1/2, N=69, Recruiting, Sponsor: Sherif Farag, MB, BS
Trial primary completion date: Jun 2015 --> Mar 2016 Trial primary completion date: Jul 2016 --> Dec 2016
- |||||||||| Zybrestat (fosbretabulin) / Oncotelic
New P2/3 trial: FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer (clinicaltrials.gov) - Dec 29, 2015
P2/3, N=436, Not yet recruiting, Sponsor: OXiGENE
- Trial completion: Multi-national, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse. (CALYPSO) (clinicaltrials.gov) - Dec 18, 2015
P3, N=8, Completed, Sponsor: King Faisal Specialist Hospital & Research Center
Trial primary completion date: Jul 2016 --> Dec 2016 Active, not recruiting --> Completed
- ||| Elahere (mirvetuximab soravtansine-gynx) / AbbVie
Enrollment open, Combination therapy, Metastases: KEYNOTE PN409: Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FR?) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Dec 16, 2015
P1, N=145, Recruiting, Sponsor: ImmunoGen, Inc.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Elahere (mirvetuximab soravtansine-gynx) / ImmunoGen
New P2 trial, Metastases: FORWARD I: A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer (clinicaltrials.gov) - Dec 16, 2015
P2, N=247, Not yet recruiting, Sponsor: ImmunoGen, Inc.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Trial primary completion date, Metastases: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) (clinicaltrials.gov) - Dec 5, 2015
P1/2, N=48, Recruiting, Sponsor: Advenchen Laboratories, LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2016 --> Jun 2016
- Avastin (bevacizumab) / Roche
Trial initiation date, Trial primary completion date, Metastases: Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative (clinicaltrials.gov) - Dec 3, 2015
P2, N=37, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2016 --> Jun 2016 Initiation date: Nov 2015 --> Mar 2016 | Trial primary completion date: Nov 2018 --> Mar 2019
- Avastin (bevacizumab) / Roche
Trial primary completion date: ENGOT-ov 17: Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer (clinicaltrials.gov) - Nov 27, 2015
P3, N=400, Recruiting, Sponsor: National Cancer Institute, Naples
Initiation date: Nov 2015 --> Mar 2016 | Trial primary completion date: Nov 2018 --> Mar 2019 Trial primary completion date: Feb 2016 --> Dec 2016
- Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Nov 24, 2015
P1/2, N=42, Completed, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Feb 2016 --> Dec 2016 Trial primary completion date: Dec 2012 --> Aug 2008
- | Rituxan (rituximab) / Roche
Enrollment open, Trial initiation date, Combination therapy, Head-to-Head: R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma (clinicaltrials.gov) - Nov 19, 2015
P3, N=216, Recruiting, Sponsor: Wenqi Jiang
Trial primary completion date: Dec 2012 --> Aug 2008 Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Sep 2015
- Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma, Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion, Avastin (bevacizumab) / Roche
Trial primary completion date: Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Nov 17, 2015
P2, N=60, Recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Sep 2015 Trial primary completion date: Jun 2018 --> Jun 2020
- ||| Elahere (mirvetuximab soravtansine-gynx) / AbbVie
New P1 trial, Combination therapy, Metastases: KEYNOTE PN409: Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FR?) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Nov 17, 2015
P1, N=145, Not yet recruiting, Sponsor: ImmunoGen, Inc.
- |||| Imfinzi (durvalumab) / AstraZeneca, motolimod (VTX 2337) / BMS
Enrollment open: Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer (clinicaltrials.gov) - Nov 17, 2015
P1/2, N=53, Recruiting, Sponsor: Ludwig Institute for Cancer Research
Trial primary completion date: Jun 2018 --> Jun 2020 Not yet recruiting --> Recruiting
- Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma, veliparib (ABT-888) / AbbVie
Trial primary completion date, PARP Biomarker, Metastases: Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer (clinicaltrials.gov) - Nov 10, 2015
P1, N=58, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2015 --> Oct 2016
- Trial completion, Enrollment change, Trial primary completion date: AMVAC: Dose Dense MVAC for Muscle Invasive Bladder Cancer (clinicaltrials.gov) - Nov 10, 2015
P2, N=54, Completed, Sponsor: Fox Chase Cancer Center
Trial primary completion date: Dec 2015 --> Oct 2016 Active, not recruiting --> Completed | N=42 --> 54 | Trial primary completion date: Dec 2015 --> Jul 2013
- bortezomib / Generic mfg., pegylated liposomal doxorubicin / Generic mfg.
Trial primary completion date: Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia (clinicaltrials.gov) - Nov 10, 2015
P2, N=30, Recruiting, Sponsor: University of California, Davis
Active, not recruiting --> Completed | N=42 --> 54 | Trial primary completion date: Dec 2015 --> Jul 2013 Trial primary completion date: Mar 2015 --> Jan 2016
- Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Trial primary completion date: Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 9, 2015
P1/2, N=47, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: Mar 2015 --> Jan 2016 Trial primary completion date: Mar 2016 --> Oct 2017
- Avastin (bevacizumab) / Roche
Trial completion, Enrollment change, Metastases: Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer (clinicaltrials.gov) - Nov 9, 2015
P2, N=31, Completed, Sponsor: Rutgers, The State University of New Jersey
Trial primary completion date: Mar 2016 --> Oct 2017 Active, not recruiting --> Completed | N=50 --> 31
- ||| Imfinzi (durvalumab) / AstraZeneca, motolimod (VTX 2337) / BMS
Trial initiation date: Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer (clinicaltrials.gov) - Oct 29, 2015
P1/2, N=53, Not yet recruiting, Sponsor: Ludwig Institute for Cancer Research
Active, not recruiting --> Completed | N=50 --> 31 Initiation date: Jun 2015 --> Oct 2015
- || Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial primary completion date, Combination therapy: Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas (clinicaltrials.gov) - Oct 27, 2015
P2, N=68, Active, not recruiting, Sponsor: University of Southern California
Initiation date: Jun 2015 --> Oct 2015 Trial primary completion date: Jun 2015 --> Jun 2016
- Zolinza (vorinostat) / Merck (MSD)
Enrollment change, Trial termination, Trial primary completion date: Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 22, 2015
P1, N=32, Terminated, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial primary completion date: Jun 2015 --> Jun 2016 N=42 --> 32 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2013 --> Dec 2011; Drugs unavailable- study terminated 1/2/18
- |||| amcasertib (BBI-503) / Sumitomo Pharma
Enrollment open, Combination therapy, PD(L)-1 Biomarker, Metastases: A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer (clinicaltrials.gov) - Oct 22, 2015
P1/2, N=200, Recruiting, Sponsor: Boston Biomedical, Inc
N=42 --> 32 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2013 --> Dec 2011; Drugs unavailable- study terminated 1/2/18 Not yet recruiting --> Recruiting
- |||||||||| Bavencio (avelumab) / EMD Serono
New P3 trial, Combination therapy, PD(L)-1 Biomarker, IO biomarker: A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) (clinicaltrials.gov) - Oct 22, 2015
P3, N=550, Not yet recruiting, Sponsor: Pfizer
- Focus V (anlotinib) / Advenchen, Sino Biopharm
New P1/2 trial, Metastases: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) (clinicaltrials.gov) - Oct 22, 2015
P1/2, N=48, Not yet recruiting, Sponsor: Advenchen Laboratories, LLC
- sirolimus / Generic mfg.
Enrollment open, Enrollment change, Immune cell: Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers (clinicaltrials.gov) - Sep 29, 2015
P2, N=510, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Suspended --> Recruiting | N=352 --> 510
- || trebananib (AMG 386) / Amgen
Trial primary completion date, Combination therapy, Metastases: AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR (clinicaltrials.gov) - Sep 29, 2015
P1, N=103, Completed, Sponsor: Amgen
Suspended --> Recruiting | N=352 --> 510 Trial primary completion date: Apr 2012 --> Jan 2012
- pegylated liposomal doxorubicin / Generic mfg., carboplatin / Generic mfg.
Enrollment change, Trial termination: Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma (clinicaltrials.gov) - Sep 28, 2015
P2, N=34, Terminated, Sponsor: Hellenic Oncology Research Group
Trial primary completion date: Apr 2012 --> Jan 2012 N=100 --> 34 | Withdrawn --> Terminated; Poor accrual
- Rituxan (rituximab) / Roche
Trial primary completion date: Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma (clinicaltrials.gov) - Sep 25, 2015
P2, N=25, Active, not recruiting, Sponsor: Northwestern University
N=100 --> 34 | Withdrawn --> Terminated; Poor accrual Trial primary completion date: Oct 2015 --> Oct 2016
- pegylated liposomal doxorubicin / Generic mfg.
New trial: HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors (clinicaltrials.gov) - Sep 23, 2015
P=N/A, N=0, Withheld, Sponsor: [Redacted]
- Trial termination: Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Sep 21, 2015
P1/2, N=31, Terminated, Sponsor: University of Washington
Trial primary completion date: Oct 2015 --> Oct 2016 Active, not recruiting --> Terminated; One of the study drugs is not available.
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial primary completion date: Doxil, Bevacizumab and Temsirolimus Trial (clinicaltrials.gov) - Sep 9, 2015
P1, N=206, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Terminated; One of the study drugs is not available. Trial primary completion date: Aug 2016 --> Aug 2017
- Trial primary completion date: A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer (clinicaltrials.gov) - Sep 8, 2015
P1, N=24, Recruiting, Sponsor: Fox Chase Cancer Center
Trial primary completion date: Aug 2016 --> Aug 2017 Trial primary completion date: Dec 2014 --> Dec 2015
- |||| trebananib (AMG 386) / Amgen
Trial primary completion date: AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) (clinicaltrials.gov) - Sep 8, 2015
P3, N=223, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Nov 2014 --> Aug 2014
- Trial primary completion date: AMVAC: Dose Dense MVAC for Muscle Invasive Bladder Cancer (clinicaltrials.gov) - Sep 8, 2015
P2, N=42, Active, not recruiting, Sponsor: Fox Chase Cancer Center
Trial primary completion date: Nov 2014 --> Aug 2014 Trial primary completion date: Dec 2014 --> Dec 2015
- ||||| Avastin (bevacizumab) / Roche
Enrollment closed: ENGOT ov-18: Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer (clinicaltrials.gov) - Aug 26, 2015
P3, N=682, Active, not recruiting, Sponsor: AGO Research GmbH
Trial primary completion date: Dec 2014 --> Dec 2015 Recruiting --> Active, not recruiting
- Ninlaro (ixazomib) / Takeda
Enrollment open: Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia (clinicaltrials.gov) - Aug 25, 2015
P1, N=18, Recruiting, Sponsor: Ehab L Atallah
Recruiting --> Active, not recruiting Suspended --> Recruiting
- Recentin (cediranib) / AstraZeneca, Lynparza (olaparib) / Merck (MSD), AstraZeneca
BRCA Biomarker, PARP Biomarker: COCOS: Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer (clinicaltrials.gov) - Aug 21, 2015
P2/3, N=680, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Trial primary completion date: Aug 2020 --> Jun 2023
- sirolimus / Generic mfg.
Enrollment change, Trial suspension, Immune cell: Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers (clinicaltrials.gov) - Aug 21, 2015
P2, N=336, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Aug 2020 --> Jun 2023 N=510 --> 336 | Recruiting --> Suspended
- pegylated liposomal doxorubicin / Generic mfg., nintedanib / Generic mfg.
Trial primary completion date, Combination therapy: Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer (clinicaltrials.gov) - Aug 19, 2015
P1/2, N=11, Terminated, Sponsor: Hoosier Cancer Research Network
N=510 --> 336 | Recruiting --> Suspended Trial primary completion date: Jun 2015 --> Dec 2015
- ||| trebananib (AMG 386) / Amgen
Trial completion, Combination therapy, Metastases: AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR (clinicaltrials.gov) - Aug 14, 2015
P1, N=103, Completed, Sponsor: Amgen
Trial primary completion date: Jun 2015 --> Dec 2015 Active, not recruiting --> Completed
- |||| Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma, Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion, Avastin (bevacizumab) / Roche
Enrollment open: Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Jul 25, 2015
P2, N=60, Recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- pegylated liposomal doxorubicin / Generic mfg.
Trial completion, Metastases: Liposomal Doxorubicin in Treating Patients With Stage IIB, Stage IVA, or Stage IVB Recurrent or Refractory Mycosis Fungoides (clinicaltrials.gov) - Jul 17, 2015
P2, N=49, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma (clinicaltrials.gov) - Jul 14, 2015
P2, N=55, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Jul 2015
- | nibrozetone (RRx-001) / EpicentRx
New P2 trial: RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) (clinicaltrials.gov) - Jul 6, 2015
P2, N=90, Recruiting, Sponsor: EpicentRx, Inc.
- pegylated liposomal doxorubicin / Generic mfg., cyclophosphamide / Generic mfg.
Enrollment closed, Trial primary completion date: Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer (clinicaltrials.gov) - Jul 1, 2015
P1, N=18, Active, not recruiting, Sponsor: Columbia University
Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Jul 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2013 --> Sep 2012
- ||||| amcasertib (BBI-503) / Sumitomo Pharma
New P1/2 trial, Combination therapy, PD(L)-1 Biomarker, Metastases: A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer (clinicaltrials.gov) - Jun 26, 2015
P1/2, N=200, Not yet recruiting, Sponsor: Boston Biomedical, Inc
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial primary completion date: Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma (clinicaltrials.gov) - Jun 18, 2015
P1, N=40, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2013 --> Sep 2012 Trial primary completion date: Jun 2023 --> Jun 2022
- Enrollment change, Trial withdrawal, Metastases: Single Dose of Intravenous rhTNF-? and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov) - Jun 16, 2015
P1, N=0, Withdrawn, Sponsor: Ludwig Institute for Cancer Research
Trial primary completion date: Jun 2023 --> Jun 2022 N=21 --> 0 | Suspended --> Withdrawn
- pegylated liposomal doxorubicin / Generic mfg., carboplatin / Generic mfg., paclitaxel / Generic mfg.
Enrollment open, Surgery: Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer (clinicaltrials.gov) - Jun 12, 2015
P2, N=60, Recruiting, Sponsor: Rutgers, The State University of New Jersey
N=21 --> 0 | Suspended --> Withdrawn Not yet recruiting --> Recruiting